HARBIN GLORIA PHARMACEUTICALS Co., LTD

SZSE:002437 주식 보고서

시가총액: CN¥5.5b

HARBIN GLORIA PHARMACEUTICALS 과거 수익 실적

과거 기준 확인 2/6

HARBIN GLORIA PHARMACEUTICALS has been growing earnings at an average annual rate of 62.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 12.8% per year. HARBIN GLORIA PHARMACEUTICALS's return on equity is 4.7%, and it has net margins of 3.3%.

주요 정보

62.9%

수익 성장률

62.9%

EPS 성장률

Pharmaceuticals 산업 성장10.9%
매출 성장률-12.8%
자기자본 수익률4.7%
순이익3.3%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations

Nov 04
HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations

Recent updates

HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations

Nov 04
HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations

Insufficient Growth At HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Hampers Share Price

Jul 03
Insufficient Growth At HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Hampers Share Price

Why HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Earnings Are Better Than They Seem

Apr 22
Why HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Earnings Are Better Than They Seem

수익 및 비용 분석

HARBIN GLORIA PHARMACEUTICALS 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SZSE:002437 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 242,432801,00574
30 Jun 242,4152171,07177
31 Mar 242,5381531,19086
31 Dec 232,6261201,24485
30 Sep 232,745-9889287
30 Jun 232,941-2901,156101
31 Mar 233,015-2721,32995
01 Jan 233,108-2911,518101
30 Sep 223,242-352,157114
30 Jun 223,207-432,09492
31 Mar 223,214242,09491
01 Jan 223,145452,05898
30 Sep 213,159-1472,213119
30 Jun 213,187-1542,260132
31 Mar 213,179-2372,264136
31 Dec 203,0554002,185125
30 Sep 203,291-2,3142,195172
30 Jun 203,725-2,2252,344177
31 Mar 204,376-2,0892,659183
31 Dec 195,054-2,6623,043186
30 Sep 195,4961223,385119
30 Jun 195,6781323,562107
31 Mar 195,5411133,447115
31 Dec 185,4811263,365122
30 Sep 185,0153373,023119
30 Jun 184,3143162,498138
31 Mar 183,6412872,001105
31 Dec 173,0423101,47780
30 Sep 172,8824341,01442
30 Jun 172,8925828510
31 Mar 172,9676737610
31 Dec 162,9847177700
30 Sep 162,8457367440
30 Jun 162,7736957540
31 Mar 162,7707047850
31 Dec 152,6816657800
30 Sep 152,4626457140
30 Jun 152,2645657040
31 Mar 152,1285027050
31 Dec 141,9064446540
30 Sep 141,7303906800
30 Jun 141,5973377080
31 Mar 141,4052748010
31 Dec 131,3082278010

양질의 수익: 002437 has a large one-off gain of CN¥94.7M impacting its last 12 months of financial results to 30th September, 2024.

이익 마진 증가: 002437 became profitable in the past.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 002437's earnings have grown significantly by 62.9% per year over the past 5 years.

성장 가속화: 002437 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

수익 대 산업: 002437 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).

자기자본 수익률

높은 ROE: 002437's Return on Equity (4.7%) is considered low.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

7D

1Y

7D

1Y

7D

1Y